Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D0463 | olanzapine

Molecular Formula C17H20N4S
Molecular Weight 312.4
Structure
State solid
Clearance The mean clearance rate of olanzapine is of 29.4 L/hour however, some studies have reported an apparent clearance of 25 L/h.[T554]
Volume of distribution The volume of distribution of olanzapine is reported to be of 1000 liters which indicate a large distribution throughout the body.[A177014]
Route of elimination Olanzapine is mainly eliminated through metabolism and hence, only 7% of the eliminated drug can be found as the unchanged form. It is mainly excreted in the urine which represents around 53% of the excreted dose followed by the feces that represent about 30%.[A177014]
Protein binding Olanzapine is largely bound to plasma proteins and hence, about 93% of the administered dose is bound. The main proteins for binding are albumin and alpha-1 acid glycoprotein.[A177014]
Half life Olanzapine presents a half-life ranging between 21 to 54 hours with an average half-life of 30 hours.[A177014]
Absorption Olanzapine presents a linear pharmacokinetic profile and, after daily administration, it reaches steady-state in about a week.[A177014] Under the administration of a normal dosage of olanzapine, the steady-state plasma concentration does not seem to exceed 150 ng/ml with an AUC of 333 ng/h/ml.[A177059, T554] The absorption of olanzapine is not affected by the concomitant administration of food. The pharmacokinetic profile of olanzapine is characterized by reaching peak plasma concentration of 156.9 ng/ml approximately 6 hours after oral administration.[T548]

N

N05AH03 Olanzapine


[N05AH] Diazepines, oxazepines, thiazepines and oxepines


[N05A] ANTIPSYCHOTICS


[N05] PSYCHOLEPTICS


[N] Nervous system

Toxicity Dose Time Species Model Method Action Positive criterion Reference
ELECTRON TRANSPORT CHAIN rat isolated liver mitochondria Negative 23

Target Dose Time Species Model Method Action Positive criterion Reference
NADH:ubiquinone reductase rat isolated liver mitochondria Negative 23

Pictogram Signal Statements Precautionary Statement Codes
Danger

Aggregated GHS information provided by 57 companies from 19 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


H301 (28.07%): Toxic if swallowed [Danger Acute toxicity, oral]


H315 (77.19%): Causes skin irritation [Warning Skin corrosion/irritation]


H317 (24.56%): May cause an allergic skin reaction [Warning Sensitization, Skin]


H319 (94.74%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]


H336 (14.04%): May cause drowsiness or dizziness [Warning Specific target organ toxicity, single exposure


Narcotic effects]


H373 (12.28%): Causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


 P260, P261, P264, P270, P271, P272, P280, P301+P310, P302+P352, P304+P340, P305+P351+P338, P312, P314, P321, P330, P332+P313, P333+P313, P337+P313, P362, P363, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)


  • (E)-2-methyl-4-(4-methylpiperazin-1-yl)-10H-benzo[b]thieno[2,3-e][1,4]diazepine 10H-Thieno(2,3-b)(1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- 10H-thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
    132539-06-1 2-Methyl-10-(4-methyl-piperazin-1-yl)-4H-3-thia-4,9-diaza-benzo[f]azulene 2-Methyl-4-(4-methyl-1-piperazinyl)- 10H-thieno[2,3-b][1,5]benzodiazepine
    2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
    2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine # 2-Methyl-4-(4-methylpiperazin-1-yl)-10H- thieno[2,3-b][1,5]benzodiazepin 2-Methyl-4-(4-methylpiperazin-1-yl)-10H-benzo[b]thieno[2,3-e][1,4]diazepine
    2-methyl-4-(4-methyl-1-piperazinyl) -10h-thieno[2,3-b][1,5]benzodiazepine 2-methyl-4-(4-methyl-1-piperazinyl)-10 H -thieno[2,3- b ] [1,5]benzodiazepine 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine
    2-methyl-4-(4-methyl-1-piperazinyl)-5H-thieno[3,2-c][1,5]benzodiazepine 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine 2-methyl-4-(4-methylpiperazin-1-yl)-5H-benzo[b]thieno[2,3-e][1,4]diazepine
    2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0(3),?]tetradeca-1(14),3(7),5,8,10,12-hexaene
    5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0(3),]tetradeca-1(14),3(7),5,8,10,12-hexaene 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0^{3,7}]tetradeca-1(10),3(7),5,8,11,13-hexaene 539O061
    5h-thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- A10667 A806453
    AB0013948 AB00639907-06 AB00639907-07
    AB00639907_08 AB00639907_09 AB1008596
    AC-665 ACMC-209wx7 ACN-029909
    ACT03231 AKOS000282888 AKOS005566122
    ALBB-027265 ALKS-7921 ANW-46937
    BCP04917 BCP9001021 BDBM35254
    BDBM82479 BIDD:GT0332 BIDD:PXR0138
    BR-57874 C07322 C17H20N4S
    CAS-132539-06-1 CAS_132539-06-1 CCG-100922
    CHEBI:7735 CHEBI:94534 CHEMBL715
    CO0033 CPD000466345 CS-1114
    CTK0H7090 CTK6I2959 Certified Reference Material
    D00454 DB00334 DSSTox_CID_3388
    DSSTox_GSID_23388 DSSTox_RID_77010 DTXSID9023388
    EBD23216 FT-0612957 GTPL47
    HMS2051H05 HMS2089M04 HMS2093I04
    HMS2233F24 HMS3374L02 HMS3393H05
    HMS3657I15 HMS3714J03 HMS3743A09
    HSDB 8155 HY-14541 I960
    J-006186 J10363 KS-00000XJV
    KS-1090 KSC177A9B KVWDHTXUZHCGIO-UHFFFAOYSA-N
    L000455 L005958 LS-152313
    LY 170053 LY-170052 LY-170053
    LY170053 Lanzac Lanzac
    MCULE-1620364835 MFCD00866702 MLS000759457
    MLS001165781 MLS001195646 MLS001424057
    Midax N7U69T4SZR NC00172
    NCGC00096077-01 NCGC00096077-03 NCGC00096077-04
    NCGC00096077-05 NCGC00096077-06 NCGC00389791-02
    NSC_4585 O0393 Oferta
    Olansek Olanzapin Olanzapine (JAN/USAN/INN)
    Olanzapine (LY-170053) Olanzapine (OLA) Olanzapine (Zyprexa)
    Olanzapine 1.0 mg/ml in Acetonitrile Olanzapine Mylan Olanzapine Neopharma
    Olanzapine Teva Olanzapine [USAN:INN] Olanzapine [USAN:USP:INN:BAN]
    Olanzapine for system suitability, European Pharmacopoeia (EP) Reference Standard Olanzapine solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material; Olanzapine(Zyprexa)
    Olanzapine, >=98% (HPLC) Olanzapine, European Pharmacopoeia (EP) Reference Standard Olanzapine, Pharmaceutical Secondary Standard
    Olanzapine, United States Pharmacopeia (USP) Reference Standard Olanzapine-d8, 100 mug/mL in acetonitrile, ampule of 1 mL, certified reference material Olzapin
    Q201872 RT-003566 S-4287
    SAM001246652 SBI-0206786.P001 SC-16244
    SCHEMBL117695 SCHEMBL28763 SMR000466345
    SPECTRUM1505024 SR-01000759343 SR-01000759343-4
    SR-01000759343-6 ST2417070 STK634338
    STL388024 SW220248-1 Tox21_111556
    Tox21_111556_1 UNII-N7U69T4SZR US8802672, Olanzapine
    Z1868057799 ZINC3873830 ZINC52957434
    Zalasta Zolafren Zypadhera
    Zyprexa Zyprexa Zyprexa Intramuscular
    Zyprexa Velotab Zyprexa Zydis olanzapina
    olanzapine olanzapinum s2493

    DrugBank Name olanzapine
    DrugBank DB00334
    CAS Number 132539-06-1, 57-88-5
    PubChem Compound 135398745
    KEGG Compound ID C07322
    KEGG Drug D00454
    ChEBI 7735
    PharmGKB PA450688